Form 8-K - Current report:
SEC Accession No. 0000950170-23-037975
Filing Date
2023-08-03
Accepted
2023-08-03 16:11:00
Documents
14
Period of Report
2023-08-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-20230803.htm   iXBRL 8-K 54520
2 EX-99.1 dvax-ex99_1.htm EX-99.1 353859
3 GRAPHIC img191369596_0.jpg GRAPHIC 119568
  Complete submission text file 0000950170-23-037975.txt   704070

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dvax-20230803_lab.xml EX-101.LAB 12806
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dvax-20230803.xsd EX-101.SCH 2466
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dvax-20230803_pre.xml EX-101.PRE 9451
8 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20230803_htm.xml XML 4534
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 231140062
SIC: 2834 Pharmaceutical Preparations